STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)

Attributable Costs of Lung Cancer for the Colombian Health System: A Cost-of-Illness Study

(2022) Gabriel F. Torres et al.   Value in Health Regional Issues

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Lung cancer

(2021) Alesha A Thai et al.   LANCET

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

(2021) Ferdinandos Skoulidis et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study

(2021) Deirdre Cronin-Fenton et al.   Scientific Reports

STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?

(2021) Alessandro Di Federico et al.   EUROPEAN JOURNAL OF CANCER

Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes

(2020) Xiaoxia Chen et al.   Annals of Translational Medicine

NFE2L2 / KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/ PD‐L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy

(2020) Xian Xu et al.   ONCOLOGIST

Molecular profiling of non-small cell lung cancer

(2020) Marika L. Forsythe et al.   PLoS One

Genetic profile of non‐small cell lung cancer (NSCLC): A hospital‐based survey in Jinhua

(2020) Xianguo Chen et al.   Molecular Genetics & Genomic Medicine

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world

(2020) Norah J. Shire et al.   PLoS One

Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11

(2019) Linnéa La Fleur et al.   LUNG CANCER

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers

(2019) Carminia Maria Della Corte et al.   Cancer Discovery

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

(2019) Natasha B. Leighl et al.   CLINICAL CANCER RESEARCH

LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer

(2019) Laura Bonanno et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor

(2019) Youjin Kim et al.   Journal of Thoracic Oncology

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

(2019) Narjust Duma et al.   MAYO CLINIC PROCEEDINGS

Association between LKB1 expression and prognosis of patients with solid tumours: an updated systematic review and meta-analysis

(2019) Yun Hong Ren et al.   BMJ Open

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

LKB1 deficiency renders non-small-cell lung cancer cells sensitive to ERK inhibitors.

(2019) Elisa Caiola et al.   Journal of Thoracic Oncology

The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity

(2019) Chengming Liu et al.   CANCER LETTERS

Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment

(2018) Sarah A. Best et al.   Cell Metabolism

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis of Distant Metastasis of Lung Cancer: Based on Clinical and Radiomic Features

(2018) Hongyu Zhou et al.   Translational Oncology

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

(2018) Ferdinandos Skoulidis et al.   Cancer Discovery

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer

(2018) Shunsuke Kitajima et al.   Cancer Discovery

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

(2016) S. Koyama et al.   CANCER RESEARCH

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

COSMIC: somatic cancer genetics at high-resolution

(2016) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

(2015) A. Drilon et al.   CLINICAL CANCER RESEARCH

Genetic alterations defining NSCLC subtypes and their therapeutic implications

(2013) Larissa A. Pikor et al.   LUNG CANCER

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

(2008) G. J. Riely et al.   CLINICAL CANCER RESEARCH